Compare Humana Inc (HUM) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Humana Inc vs Xylem, Inc. — how do they compare? Humana Inc trades at $374.25 (market cap $46.31B), while Xylem, Inc. trades at $123.19 (market cap $28.30B). The key difference: Humana Inc is the larger of the two by market cap, and Xylem, Inc. pays the higher dividend (1.42%). Which is the better fit depends on your goals.
| HUM | XYL | |
|---|---|---|
Market Cap | $46.31B | $28.30B |
Sector | Health | Industrials |
52-Week High | $409.42 | $152.95 |
52-Week Low | $163.67 | $106.34 |
Enterprise Value | $53.67B | $30.08B |
Dividend Yield | 0.92% | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Humana (HUM) trades at $385.00, up 4.82% today, with a bullish technical outlook and analyst consensus price target of $399.53. Recent earnings beats in Q1 and Q2 2026, alongside revenue growth to $129.66 billion in 2025, support fundamentals, though net margins have compressed. The company is expanding its Medicaid business and targeting margin improvements by 2027.
The stock offers upside to consensus targets but faces risks from Medicare Advantage margin pressures and regulatory changes. Profitability trends are weak despite revenue growth, requiring successful cost management to meet 2028 targets. Institutional sentiment is mixed with a majority hold rating.
Xylem (XYL) trades at $120.32, down 0.36% on the day, with a neutral technical signal and key support at $120. The company reported strong Q2 2026 earnings of $1.46 per share, beating estimates, and raised its full-year profit guidance. Revenue growth has been steady, reaching $9.04B in 2025, with net income margins improving to 10.59%. Analyst sentiment is mixed, with a consensus price target of $150.43, implying significant upside from current levels.
The outlook for XYL is positive, driven by robust demand in water technology and AI infrastructure, alongside margin expansion. Key risks include project delays in electric metering and competitive pressures. With a P/E of 28.65, the stock trades at a premium, but continued execution on earnings and strategic acquisitions supports a constructive view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
